La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
IDEXX Laboratories Résultats passés
Passé contrôle des critères 3/6
IDEXX Laboratories a connu une croissance annuelle moyenne de ses bénéfices de 14%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 11.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.2% par an. Le rendement des capitaux propres de IDEXX Laboratories est 53.5% et ses marges nettes sont de 22.3%.
Informations clés
14.0%
Taux de croissance des bénéfices
14.8%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie | 8.9% |
Taux de croissance des recettes | 10.2% |
Rendement des fonds propres | 53.5% |
Marge nette | 22.3% |
Prochaine mise à jour des résultats | 31 Oct 2024 |
Mises à jour récentes des performances passées
Recent updates
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23Ventilation des recettes et des dépenses
Comment IDEXX Laboratories gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 3,785 | 846 | 934 | 208 |
31 Mar 24 | 3,725 | 867 | 925 | 199 |
31 Dec 23 | 3,661 | 845 | 902 | 191 |
30 Sep 23 | 3,588 | 823 | 888 | 183 |
30 Jun 23 | 3,514 | 791 | 877 | 183 |
31 Mar 23 | 3,431 | 699 | 858 | 259 |
31 Dec 22 | 3,367 | 679 | 851 | 255 |
30 Sep 22 | 3,340 | 670 | 848 | 257 |
30 Jun 22 | 3,309 | 664 | 840 | 249 |
31 Mar 22 | 3,274 | 735 | 821 | 164 |
31 Dec 21 | 3,215 | 745 | 796 | 161 |
30 Sep 21 | 3,135 | 757 | 770 | 154 |
30 Jun 21 | 3,047 | 728 | 777 | 152 |
31 Mar 21 | 2,858 | 674 | 739 | 146 |
31 Dec 20 | 2,707 | 582 | 735 | 141 |
30 Sep 20 | 2,591 | 497 | 717 | 138 |
30 Jun 20 | 2,475 | 460 | 674 | 134 |
31 Mar 20 | 2,457 | 437 | 681 | 135 |
31 Dec 19 | 2,407 | 428 | 669 | 133 |
30 Sep 19 | 2,351 | 423 | 657 | 128 |
30 Jun 19 | 2,291 | 407 | 642 | 123 |
31 Mar 19 | 2,252 | 390 | 638 | 120 |
31 Dec 18 | 2,213 | 377 | 632 | 118 |
30 Sep 18 | 2,170 | 330 | 621 | 117 |
30 Jun 18 | 2,117 | 307 | 610 | 115 |
31 Mar 18 | 2,045 | 284 | 596 | 112 |
31 Dec 17 | 1,969 | 263 | 575 | 109 |
30 Sep 17 | 1,906 | 277 | 561 | 106 |
30 Jun 17 | 1,862 | 263 | 547 | 104 |
31 Mar 17 | 1,820 | 245 | 534 | 102 |
31 Dec 16 | 1,775 | 222 | 522 | 101 |
30 Sep 16 | 1,732 | 214 | 516 | 101 |
30 Jun 16 | 1,690 | 202 | 502 | 100 |
31 Mar 16 | 1,637 | 192 | 493 | 99 |
31 Dec 15 | 1,602 | 192 | 482 | 100 |
30 Sep 15 | 1,554 | 174 | 475 | 99 |
30 Jun 15 | 1,531 | 182 | 467 | 99 |
31 Mar 15 | 1,508 | 182 | 457 | 100 |
31 Dec 14 | 1,486 | 182 | 448 | 98 |
30 Sep 14 | 1,488 | 199 | 435 | 96 |
30 Jun 14 | 1,443 | 193 | 422 | 93 |
31 Mar 14 | 1,405 | 190 | 409 | 89 |
31 Dec 13 | 1,377 | 188 | 401 | 88 |
30 Sep 13 | 1,343 | 188 | 381 | 87 |
Des revenus de qualité: IDXX a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de IDXX (22.3%) sont inférieures à celles de l'année dernière (22.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de IDXX ont augmenté de 14% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de IDXX au cours de l'année écoulée ( 6.8% ) est inférieure à sa moyenne sur 5 ans ( 14% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices IDXX au cours de l'année écoulée ( 6.8% ) n'a pas surpassé celle du secteur Medical Equipment 7.2%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de IDXX ( 53.5% ) est considéré comme exceptionnel.